P J Morley|L Dash|H C Jackson - JoVE Visualize

Showing results (71-80 of 82) with videos related to

Pageof 9

Sort By:

Antimicrobial Agents and Chemotherapy|June 1, 1996

6,7-disubstituted 2,4-diaminopteridines: novel inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductaseH C Jackson, K Biggadike, E McKilligin, et al.

European Journal of Pharmacology|July 11, 1996

Anticonvulsant profile of the imidazoquinazolines NNC 14-0185 and NNC 14-0189 in rats and miceH C Jackson, H C Hansen, M Kristiansen, et al.

European Journal of Immunology|March 1, 1995

CD40 ligand is functionally expressed on human eosinophilsJ F Gauchat, S Henchoz, D Fattah, et al.

JAMA|February 15, 2001

Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trialR Welliver, A S Monto, O Carewicz, et al.

FEBS Letters|November 30, 2000

Studies on the interaction between TWEAK and the death receptor WSL-1/TRAMP (DR3)A Kaptein, M Jansen, G Dilaver, et al.

Cytokine|August 18, 2001

Modified peptide antagonists of interleukin 5 exhibit extended in vivo persistence but restricted species specificityI J Uings, P Balasubramanian, P G McLoughlin, et al.

Journal of Clinical Immunology|July 9, 2013

Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-α receptor 1M C Holland, J U Wurthner, P J Morley, et al.

Clinical and Experimental Immunology|July 17, 2015

Specificity of human anti-variable heavy (VH ) chain autoantibodies and impact on the design and clinical testing of a VH domain antibody antagonist of tumour necrosis factor-α receptor 1J C Cordy, P J Morley, T J Wright, et al.

Antimicrobial Agents and Chemotherapy|December 22, 1999

Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studiesJ M Barnett, A Cadman, D Gor, et al.

Journal of Medicinal Chemistry|April 4, 1998

Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamidesP W Smith, S L Sollis, P D Howes, et al.

Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:

Pageof 9

Antimicrobial Agents and Chemotherapy|June 1, 1996

6,7-disubstituted 2,4-diaminopteridines: novel inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductaseH C Jackson, K Biggadike, E McKilligin, et al.

European Journal of Pharmacology|July 11, 1996

Anticonvulsant profile of the imidazoquinazolines NNC 14-0185 and NNC 14-0189 in rats and miceH C Jackson, H C Hansen, M Kristiansen, et al.

European Journal of Immunology|March 1, 1995

CD40 ligand is functionally expressed on human eosinophilsJ F Gauchat, S Henchoz, D Fattah, et al.

JAMA|February 15, 2001

Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trialR Welliver, A S Monto, O Carewicz, et al.

FEBS Letters|November 30, 2000

Studies on the interaction between TWEAK and the death receptor WSL-1/TRAMP (DR3)A Kaptein, M Jansen, G Dilaver, et al.

Cytokine|August 18, 2001

Modified peptide antagonists of interleukin 5 exhibit extended in vivo persistence but restricted species specificityI J Uings, P Balasubramanian, P G McLoughlin, et al.

Journal of Clinical Immunology|July 9, 2013

Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-α receptor 1M C Holland, J U Wurthner, P J Morley, et al.

Clinical and Experimental Immunology|July 17, 2015

Specificity of human anti-variable heavy (VH ) chain autoantibodies and impact on the design and clinical testing of a VH domain antibody antagonist of tumour necrosis factor-α receptor 1J C Cordy, P J Morley, T J Wright, et al.

Antimicrobial Agents and Chemotherapy|December 22, 1999

Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studiesJ M Barnett, A Cadman, D Gor, et al.

Journal of Medicinal Chemistry|April 4, 1998

Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamidesP W Smith, S L Sollis, P D Howes, et al.

Pageof 9